Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.54 |
| ▸ | GRM5 | P41594 | 11/20 | 0.54 |
| ▸ | WNT3A | P56704 | 1/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15024195 | 0.88 | GRM1 (0.60) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL20074575 | 0.84 | GRM1 (0.56) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL25219088 | 0.84 | GRM1 (0.56) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL29950613 | 0.83 | GRM1 (0.55) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL24180524 | 0.83 | GRM1 (0.53) | GRM1GRM5WNT3APDK4TNK2 | |
| SCHEMBL30930896 | 0.83 | ESR2 (0.40) | GRM1GRM5 | |
| SCHEMBL4152429 | 0.83 | GRM1 (0.54) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL12543411 | 0.82 | GRM1 (0.56) | GRM1GRM5WNT3APDK4CDK9 | |
| SCHEMBL4251822 | 0.81 | GRM5 (0.70) | GRM1GRM5WNT3APDK4NAMPT | |
| SCHEMBL29559340 | 0.81 | GRM5 (0.70) | GRM1GRM5WNT3APDK4NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-02-02 | — | — | US | disclosed |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-02-20 | — | — | US | disclosed |
| EP-3527570-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018068759-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906905-B2 | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof | TGFBR1, TGFB2, TGFB1 | GRM1 4070/4885GRM5 1869/4885WNT3A 412/4885 |
| US-20200055852-A1 | FIVE-MEMBERED HETEROARYL RING BRIDGED RING DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | TGFBR1, TGFB2, TGFB1 | GRM1 4070/4885GRM5 1869/4885WNT3A 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.